Which has better earnings & valuation, IFRX or PROK?

InflaRx has higher earnings, but lower revenue than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $30K 5,397.65 -$51.63M -$0.71 N/A ProKidney $890K 692.36 -$68.99M -$0.53 N/A

Is IFRX or PROK more profitable?

InflaRx has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -88.30% -65.77% ProKidney -8,131.50% N/A -21.39%

Does the media refer more to IFRX or PROK?

In the previous week, InflaRx and InflaRx both had 2 articles in the media. InflaRx's average media sentiment score of 1.89 beat ProKidney's score of 0.93 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AQST or IFRX?

In the previous week, Aquestive Therapeutics had 3 more articles in the media than InflaRx. MarketBeat recorded 5 mentions for Aquestive Therapeutics and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.89 beat Aquestive Therapeutics' score of 0.39 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InflaRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings & valuation, ALT or IFRX?

InflaRx has lower revenue, but higher earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Altimmune $40K 14,706.79 -$88.09M -$0.93 N/A InflaRx $30K 5,397.65 -$51.63M -$0.71 N/A

Is ALT or IFRX more profitable?

InflaRx has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets Altimmune -214,860.98% -42.57% -35.57% InflaRx N/A -88.30% -65.77%

Does the media refer more to ALT or IFRX?

In the previous week, Altimmune had 1 more articles in the media than InflaRx. MarketBeat recorded 3 mentions for Altimmune and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.89 beat Altimmune's score of 0.58 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InflaRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is IFRX or IMMX more profitable?

Immix Biopharma's return on equity of -73.24% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -88.30% -65.77% Immix Biopharma N/A -73.24% -59.20%

Does the media prefer IFRX or IMMX?

In the previous week, InflaRx and InflaRx both had 2 articles in the media. InflaRx's average media sentiment score of 1.89 beat Immix Biopharma's score of 0.96 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, IFRX or RGNX?

InflaRx has higher earnings, but lower revenue than REGENXBIO. InflaRx is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $30K 5,397.65 -$51.63M -$0.71 N/A REGENXBIO $170.44M 3.63 -$193.88M -$5.60 N/A

Is IFRX or RGNX more profitable?

InflaRx has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. InflaRx's return on equity of -88.30% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -88.30% -65.77% REGENXBIO -330.23% -232.50% -61.02%

Does the media favor IFRX or RGNX?

In the previous week, REGENXBIO had 5 more articles in the media than InflaRx. MarketBeat recorded 7 mentions for REGENXBIO and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.89 beat REGENXBIO's score of 0.43 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

InflaRx (IFRX) Competitors

$2.24 -0.04 (-1.75%)

Closing price 04:00 PM Eastern

Extended Trading

$2.25 +0.01 (+0.27%)

As of 07:21 PM Eastern

Compare

IFRX vs. PROK, AQST, ALT, IMMX, and RGNX

Should you buy InflaRx stock or one of its competitors? MarketBeat compares InflaRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InflaRx include ProKidney (PROK), Aquestive Therapeutics (AQST), Altimmune (ALT), Immix Biopharma (IMMX), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry.

How does InflaRx compare to ProKidney?

InflaRx (NASDAQ:IFRX) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

InflaRx presently has a consensus target price of $7.00, suggesting a potential upside of 212.50%. ProKidney has a consensus target price of $9.00, suggesting a potential upside of 341.18%. Given ProKidney's higher probable upside, analysts clearly believe ProKidney is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
ProKidney	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

InflaRx has a beta of 2.42, indicating that its share price is 142% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market.

42.4% of InflaRx shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

InflaRx has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-88.30%	-65.77%
ProKidney	-8,131.50%	N/A	-21.39%

In the previous week, InflaRx and InflaRx both had 2 articles in the media. InflaRx's average media sentiment score of 1.89 beat ProKidney's score of 0.93 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InflaRx has higher earnings, but lower revenue than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	5,397.65	-$51.63M	-$0.71	N/A
ProKidney	$890K	692.36	-$68.99M	-$0.53	N/A

Summary

ProKidney beats InflaRx on 7 of the 13 factors compared between the two stocks.

How does InflaRx compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

InflaRx has lower revenue, but higher earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.72	-$83.78M	-$0.61	N/A
InflaRx	$30K	5,397.65	-$51.63M	-$0.71	N/A

Aquestive Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 104.33%. InflaRx has a consensus target price of $7.00, indicating a potential upside of 212.50%. Given InflaRx's higher probable upside, analysts clearly believe InflaRx is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Aquestive Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.42, indicating that its stock price is 142% more volatile than the broader market.

32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by insiders. Comparatively, 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

InflaRx has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
InflaRx	N/A	-88.30%	-65.77%

In the previous week, Aquestive Therapeutics had 3 more articles in the media than InflaRx. MarketBeat recorded 5 mentions for Aquestive Therapeutics and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.89 beat Aquestive Therapeutics' score of 0.39 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InflaRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

InflaRx beats Aquestive Therapeutics on 9 of the 16 factors compared between the two stocks.

How does InflaRx compare to Altimmune?

Altimmune (NASDAQ:ALT) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

In the previous week, Altimmune had 1 more articles in the media than InflaRx. MarketBeat recorded 3 mentions for Altimmune and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.89 beat Altimmune's score of 0.58 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InflaRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Altimmune presently has a consensus price target of $15.71, suggesting a potential upside of 419.48%. InflaRx has a consensus price target of $7.00, suggesting a potential upside of 212.50%. Given Altimmune's higher possible upside, equities analysts plainly believe Altimmune is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

InflaRx has lower revenue, but higher earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	14,706.79	-$88.09M	-$0.93	N/A
InflaRx	$30K	5,397.65	-$51.63M	-$0.71	N/A

Altimmune has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, InflaRx has a beta of 2.42, suggesting that its share price is 142% more volatile than the broader market.

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 1.6% of Altimmune shares are owned by company insiders. Comparatively, 16.3% of InflaRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

InflaRx has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
InflaRx	N/A	-88.30%	-65.77%

Summary

InflaRx beats Altimmune on 9 of the 17 factors compared between the two stocks.

How does InflaRx compare to Immix Biopharma?

InflaRx (NASDAQ:IFRX) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

InflaRx currently has a consensus price target of $7.00, suggesting a potential upside of 212.50%. Immix Biopharma has a consensus price target of $20.67, suggesting a potential upside of 100.45%. Given InflaRx's stronger consensus rating and higher probable upside, research analysts plainly believe InflaRx is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

42.4% of InflaRx shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 30.3% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Immix Biopharma's return on equity of -73.24% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-88.30%	-65.77%
Immix Biopharma	N/A	-73.24%	-59.20%

InflaRx has a beta of 2.42, indicating that its share price is 142% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

In the previous week, InflaRx and InflaRx both had 2 articles in the media. InflaRx's average media sentiment score of 1.89 beat Immix Biopharma's score of 0.96 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immix Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immix Biopharma has lower revenue, but higher earnings than InflaRx. Immix Biopharma is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	5,397.65	-$51.63M	-$0.71	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

Summary

InflaRx beats Immix Biopharma on 9 of the 14 factors compared between the two stocks.

How does InflaRx compare to REGENXBIO?

InflaRx (NASDAQ:IFRX) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

InflaRx has a beta of 2.42, indicating that its stock price is 142% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

InflaRx has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. InflaRx's return on equity of -88.30% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-88.30%	-65.77%
REGENXBIO	-330.23%	-232.50%	-61.02%

In the previous week, REGENXBIO had 5 more articles in the media than InflaRx. MarketBeat recorded 7 mentions for REGENXBIO and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.89 beat REGENXBIO's score of 0.43 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
REGENXBIO	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InflaRx presently has a consensus target price of $7.00, indicating a potential upside of 212.50%. REGENXBIO has a consensus target price of $23.82, indicating a potential upside of 98.82%. Given InflaRx's higher probable upside, analysts plainly believe InflaRx is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 14.2% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

InflaRx has higher earnings, but lower revenue than REGENXBIO. InflaRx is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	5,397.65	-$51.63M	-$0.71	N/A
REGENXBIO	$170.44M	3.63	-$193.88M	-$5.60	N/A

Summary

InflaRx beats REGENXBIO on 10 of the 17 factors compared between the two stocks.

Get InflaRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IFRX vs. The Competition

Export

Metric	InflaRx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$164.83M	$3.66B	$6.87B	$12.45B
Dividend Yield	N/A	2.20%	2.67%	6.16%
P/E Ratio	-3.15	20.90	27.51	24.87
Price / Sales	5,397.65	341.80	540.69	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	3.45	8.75	11.01	6.54
Net Income	-$51.63M	$23.81M	$3.57B	$336.70M
7 Day Performance	16.06%	3.64%	2.56%	3.31%
1 Month Performance	-6.67%	1.64%	0.89%	1.68%
1 Year Performance	183.54%	69.47%	36.84%	31.96%

InflaRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IFRX InflaRx	2.7741 of 5 stars	$2.24 -1.8%	$7.00 +212.5%	+182.2%	$164.83M	$30K	N/A	60	News Coverage Positive News Gap Down
PROK ProKidney	1.9473 of 5 stars	$1.82 +6.8%	$7.40 +307.7%	+182.6%	$552.17M	$890K	N/A	3	News Coverage Positive News
AQST Aquestive Therapeutics	2.8328 of 5 stars	$4.39 -1.9%	$8.50 +93.8%	+28.0%	$547.34M	$50.27M	N/A	160
ALT Altimmune	2.0584 of 5 stars	$2.82 -1.9%	$15.71 +458.2%	-16.0%	$545.49M	$40K	N/A	50	Analyst Upgrade
IMMX Immix Biopharma	3.7229 of 5 stars	$9.96 +2.5%	$20.67 +107.4%	+383.4%	$542.74M	N/A	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IFRX) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InflaRx (IFRX) Competitors